MOTS-c treatment lowered levels of myostatin, a protein that normally limits muscle growth, in immobilized mice.

Scientific Claim

In male C57BL/6J mice with 8 days of hindlimb immobilization, daily MOTS-c administration (15 mg/kg/day) was associated with reduced myostatin expression compared to untreated controls.

Original Statement

“Immobilization-induced increased myostatin expression was suppressed by MOTS-c treatment (Fig. 1C).”

From study:Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The claim uses 'was associated with' and specifies the model and measurement without causal language, appropriate for the study design.

Evidence from Studies

Supporting (1)

Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration.

Randomized Controlled Trial

Animal

2024 Mar 1

Contradicting (0)

No contradicting evidence found

Source Study

Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration.

Score: 16

DOI: 10.1152/ajpendo.00285.2023

Similar Assertions

MOTS-c lowered levels of myostatin, a protein that inhibits muscle growth, in the muscles of immobilized mice.

91%

Mice with immobilized legs that received MOTS-c had lower levels of key inflammation markers in their blood compared to untreated mice.

86%

Mice given MOTS-c had higher levels of the peptide in their blood compared to those without treatment.

85%

MOTS-c reduced levels of several inflammatory proteins in the blood of immobilized mice, which may help reduce muscle damage.

82%

When mice had their legs immobilized for 8 days, giving them MOTS-c helped their muscles lose less weight (5% instead of 15%) compared to mice that didn't get the treatment.

82%